Full-Time

Director/Sr. Director

Business Development & Operations

Updated on 12/5/2024

BridgeBio

BridgeBio

501-1,000 employees

Develops medicines for genetic diseases

Biotechnology
Healthcare

Compensation Overview

$215k - $295kAnnually

+ Performance Bonus + Equity

Senior, Expert

Palo Alto, CA, USA

Hybrid work environment.

Category
Business Development
Business & Strategy
Required Skills
Data Analysis
Requirements
  • PhD or MD from top-tier academic institutions or scientific undergrad with commensurate work experience
  • Strategic planning, operating, and program management experience working with a close-knit team at a biotech startup or top-tier pharma
  • Management Consulting or Banking experience from top tier firm
Responsibilities
  • Learn quickly the scientific, operational, and external facing facets of Gondola programs
  • Set, prioritize, and manage milestones & deliverables for team members in one or more of the Gondola programs
  • Coordinate team meetings and delegate to technical experts in one or more of the Gondola Programs
  • Interpret, collate, and communicate key data findings in a succinct manner to senior management
  • Identify problems, locate the resources, and find data-driven solutions independent of supervision

BridgeBio Pharma develops medicines specifically for genetic diseases, focusing on conditions with well-understood genetic causes. The company uses a decentralized subsidiary model, allowing each subsidiary to concentrate on specific diseases while sharing central resources. This structure enhances efficiency and enables the advancement of multiple drug programs at once. BridgeBio utilizes advancements in genome sequencing and molecular biology to identify and develop effective treatments. Their goal is to create therapies that address the genetic roots of diseases, potentially leading to significant improvements in patient outcomes. With over 15 drug programs targeting 20 different genetic diseases, BridgeBio aims to expedite the drug development process and bring new treatments to market more quickly than traditional biopharmaceutical companies.

Company Stage

IPO

Total Funding

$704.4M

Headquarters

Palo Alto, California

Founded

2014

Growth & Insights
Headcount

6 month growth

28%

1 year growth

59%

2 year growth

97%
Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with PANTHERx® Rare enhances patient access for Attruby™.
  • $200 million funding boosts oncology efforts, especially KRAS inhibitors.
  • Norges Bank's $46.84 million investment shows strong financial backing.

What critics are saying

  • Alnylam's Amvuttra may challenge Attruby™ in ATTR-CM market.
  • KRAS inhibitors face scientific challenges due to 'undruggable' mutations.

What makes BridgeBio unique

  • BridgeBio employs a decentralized subsidiary model for rapid drug development.
  • Focuses on genetic diseases with well-understood underlying causes.
  • Leverages genome sequencing and molecular biology for targeted therapies.

Help us improve and share your feedback! Did you find this helpful?